ES2976558T3 - Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas - Google Patents

Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas Download PDF

Info

Publication number
ES2976558T3
ES2976558T3 ES18820011T ES18820011T ES2976558T3 ES 2976558 T3 ES2976558 T3 ES 2976558T3 ES 18820011 T ES18820011 T ES 18820011T ES 18820011 T ES18820011 T ES 18820011T ES 2976558 T3 ES2976558 T3 ES 2976558T3
Authority
ES
Spain
Prior art keywords
dose
cells
antibody
cell
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18820011T
Other languages
English (en)
Spanish (es)
Inventor
Ravindra Majeti
Mark P Chao
Jie Liu
Jens-Peter Volkmer
Irving L Weissman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Board Of Trustees Of Leland Stanfordjunior Univ
Forty Seven LLC
Original Assignee
Board Of Trustees Of Leland Stanfordjunior Univ
Forty Seven LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Trustees Of Leland Stanfordjunior Univ, Forty Seven LLC filed Critical Board Of Trustees Of Leland Stanfordjunior Univ
Application granted granted Critical
Publication of ES2976558T3 publication Critical patent/ES2976558T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES18820011T 2017-06-21 2018-06-21 Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas Active ES2976558T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523182P 2017-06-21 2017-06-21
PCT/US2018/038798 WO2018237168A1 (en) 2017-06-21 2018-06-21 Dosing parameters for cd47 targeting therapies to hematologic malignancies

Publications (1)

Publication Number Publication Date
ES2976558T3 true ES2976558T3 (es) 2024-08-05

Family

ID=64735831

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18820011T Active ES2976558T3 (es) 2017-06-21 2018-06-21 Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas

Country Status (12)

Country Link
US (3) US11141480B2 (https=)
EP (2) EP3642242B1 (https=)
JP (2) JP7312706B2 (https=)
KR (1) KR102757177B1 (https=)
CN (2) CN110831974B (https=)
AU (2) AU2018290248B2 (https=)
CA (1) CA3063099A1 (https=)
ES (1) ES2976558T3 (https=)
PL (1) PL3642242T3 (https=)
PT (1) PT3642242T (https=)
SI (1) SI3642242T1 (https=)
WO (1) WO2018237168A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
US11072655B2 (en) * 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
WO2018237168A1 (en) * 2017-06-21 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Dosing parameters for cd47 targeting therapies to hematologic malignancies
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
ES2973832T3 (es) * 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
CN121243368A (zh) * 2019-11-27 2026-01-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
CN111905101B (zh) * 2020-07-03 2022-09-23 中山大学 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法
WO2022007947A1 (zh) * 2020-07-10 2022-01-13 信达生物制药(苏州)有限公司 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
EP4291216A1 (en) * 2021-02-09 2023-12-20 University of Houston System Oncolytic virus for systemic delivery and enhanced anti-tumor activities
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
AU2024225341A1 (en) 2023-02-21 2025-09-04 Osteal Therapeutics, Inc. Methods of treating a localized infection with locally administered antibiotics

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543819T3 (es) 1998-11-09 2015-08-24 Biogen Inc. Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (es) * 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
CA2771336C (en) * 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
NZ710695A (en) * 2013-02-06 2020-05-29 Inhibrx Inc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CN112245586A (zh) 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
EP3046627B1 (en) 2013-09-18 2019-10-23 The Board of Trustees of the Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
CN103943054B (zh) 2014-01-27 2016-07-13 上海中航光电子有限公司 栅极驱动电路、tft阵列基板、显示面板及显示装置
KR102271434B1 (ko) 2014-09-26 2021-07-01 엘지전자 주식회사 이동단말기 및 그 제어방법
CN113528663A (zh) 2014-12-10 2021-10-22 得克萨斯州大学系统董事会 使用基因组特异性探针的循环肿瘤和肿瘤干细胞检测
WO2017053423A1 (en) * 2015-09-21 2017-03-30 Erasmus University Medical Center Anti-cd47 antibodies and methods of use
WO2018237168A1 (en) 2017-06-21 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Dosing parameters for cd47 targeting therapies to hematologic malignancies

Also Published As

Publication number Publication date
US20200147212A1 (en) 2020-05-14
PL3642242T3 (pl) 2024-05-27
CN110831974A (zh) 2020-02-21
EP3642242B1 (en) 2024-02-07
JP2023083424A (ja) 2023-06-15
AU2024227248A1 (en) 2024-10-31
US12194093B2 (en) 2025-01-14
EP4368206A2 (en) 2024-05-15
JP2020525435A (ja) 2020-08-27
US12274746B2 (en) 2025-04-15
CA3063099A1 (en) 2018-12-27
US20210401979A1 (en) 2021-12-30
EP4368206A3 (en) 2024-08-14
CN110831974B (zh) 2024-05-14
AU2018290248A1 (en) 2019-11-28
PT3642242T (pt) 2024-04-16
WO2018237168A1 (en) 2018-12-27
US20230270852A1 (en) 2023-08-31
US11141480B2 (en) 2021-10-12
EP3642242A1 (en) 2020-04-29
SI3642242T1 (sl) 2024-05-31
JP7312706B2 (ja) 2023-07-21
AU2018290248B2 (en) 2024-08-01
KR102757177B1 (ko) 2025-01-21
EP3642242A4 (en) 2021-06-23
KR20200019619A (ko) 2020-02-24
CN117065013A (zh) 2023-11-17

Similar Documents

Publication Publication Date Title
ES2976558T3 (es) Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas
JP2020517640A5 (https=)
KR102195055B1 (ko) 체크포인트 저해제와 조합된 종양용해 바이러스에 의한 암 요법
KR20200119834A (ko) 항-cd47 및 항-cd20 항체를 이용한 항암 섭생
EP3436480A1 (en) Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
JP2020517629A5 (https=)
JP2022553851A (ja) 黒色腫の処置のためのｌａｇ－３アンタゴニスト
KR20210143896A (ko) 암 요법에 사용하기 위한 세마포린-4d 길항제
US20210169913A1 (en) Fcrl6 and its uses related to cancer
WO2023064779A1 (en) Glycoprotein a repetitions predominant (garp)-binding antibodies and uses thereof
CN116496411A (zh) Afp特异性t细胞受体及其用途
US20220119523A1 (en) Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
HK40114200A (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
KR20230088768A (ko) 췌관 샘암종 치료를 위한 병용 면역치료학적 방법 및 조성물
HK40025478B (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
HK40025478A (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
HK40103499A (zh) 针对血液恶性肿瘤的cd47靶向疗法的给药参数
HK40023801A (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
HK40023801B (zh) 针对血液恶性肿瘤的cd47靶向疗法的给药参数
WO2025059507A1 (en) Combination cancer therapy methods and agents